LECTURES ON ROP

2019

Libro Retinopatía del Prematuro por la SP-ROP

 

El livro fué lanzado durante el XXIV Congreso Panamericano de Oftalmología em Cancún, México.

 

Coordinado por el Dr. Luis Porfírio Orózco Gomez, el libro Retinopatia del Prematuro, publicado para los miembros de la SP-ROP, contiene mucho material didactico y cientifico para los que trabajan en la lucha contra la ceguera por la ROP.

 

El libro está disponible completo para download.

2017

"Ojo Vigilante en ROP"

Un “Ojo vigilante en ROP”

 

No existe un mayor riesgo de la seguridad del paciente relacionado con la visión que el examen y el tratamiento de bebes prematuros en riesgo a desarrollar retinopatía de la prematuridad (ROP).

 

El examen de retinopatía de la prematuridad (ROP) y el seguimiento, es un cuidado multidisciplinario, intrahospitalario, con un lapso pequeño en el que hay que proveer el examen, tratamiento y seguimiento a tiempo oportuno.

 

Los retos incluyen proporcionar un cuidado oftálmico a los bebes que están frecuentemente muy enfermos, garantizar que se dé al paciente de alta fácilmente o una transferencia de cuidado fácil, y asegurar que los proveedores de cuidado entiendan la importancia de cumplir con las citas de seguimiento.

 

El hospital St. Luke’s y el programa Ojo vigilante para retinopatía de prematuridad (©2008 Hospital St. Luke’s de Bethlehem, Pennsylvania) ofrece a los hospitales y a los proveedores de cuidado médico una solución para asegurar la detección de ROP y su seguimiento con tiempo.

 

2017

Construyendo la Salud en el Curso de Vida

2017

Termos de Consentimientos para ROP

 

Termos de Consentimientos para Screening y Tratamientos en ROP sugeridos por miembros de la SP-ROP

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2017 Acta Ophthalmologica

 

Predictive algorithms for early detection of retinopathy of prematurity

 

Stefano Piermarocchi, Silvia Bini, Ferdinando Martini, Marianna Berton, Anna Lavini, Elena Gusson, Giorgio Marchini, Ezio Maria Padovani, Sara Macor, Silvia Pignatto, Paolo Lanzetta, Luigi Cattarossi, Eugenio Baraldi, Paola Lago

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2017 JAMA Ophthalmology

 

A Tiered Approach to Retinopathy of Prematurity Screening (TARP) Using a Weight Gain Predictive Model and a Telemedicine Model

 

Jaclyn Gurwin, Lauren A. Tomlinson, Graham E. Quinn, Gui-shuang Ying, Agnieshka Baumritter, Gil Binenbaum, for the Postnatal Growth and ROP (G-ROP) Study Group and the Telemedicine Approaches to Evaluating Acute-Phase ROP (e-ROP) Cooperative Group

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

The Colorado-retinopathy of prematurity model (CO-ROP): postnatal weight gain screening algorithm

 

Jennifer H. Cao, Brandie D. Wagner, Emily A. McCourt, Ashlee Cerda, Stefan Sillau, Alan Palestine, Robert W. Enzenauer, Rebecca B. Mets-Halgrimson, Miguel Paciuc-Beja, Jane Gralla, Rebecca S. Braverman, Anne Lynch

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2016 Ophthalmology

 

Clinical Models and Algorithms for the Prediction of Retinopathy of Prematurity A Report by the American Academy of Ophthalmology

 

Amy K. Hutchinson, Michele Melia, Michael B. Yang, Deborah K. VanderVeen, Lorri B. Wilson, Scott R. Lambert

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2016 Journal of American Academy of Pediatric Opthalmology and Strabismus

 

Colorado retinopathy of prematurity model: a multi-institutional validation study

 

Jennifer H. Cao, Brandie D. Wagner, Ashlee Cerda, Emily A. McCourt, Alan Palestine, Robert W. Enzenauer, Rebecca S. Braverman, et al

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2016 World Journal of Clinical Pedatrics

 

Retinopathy of prematurity: Past, present and future

 

Parag K Shah, Vishma Prabhu, Smita S Karandikar, Ratnesh Ranjan, Venkatapathy Narendran, Narendran Kalpana

 

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2016 British Medical Journal

 

Cohort study of growth patterns by gestational age in preterm infants developing morbidity

 

S Klevebro, P Lundgren, U Hammar, L E Smith, M Bottai, M Domellöf, C Löfqvist, B Hallberg, A Hellström

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2015 Neonatology

 

 The Specificity of the WINROP Algorithm Can Be Significantly Increased by Reassessment of the WINROP

 

Alarm Pia Lundgren, Elisabeth Stoltz Sjöström, Magnus Domellöf, Lois Smith, Carolyn Wu, Deborah VanderVeen, Ann Hellström, Chatarina Löfqvist  

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2013 Plos One

 

WINROP Identifies Severe Retinopathy of Prematurity at

an Early Stage in a Nation-Based Cohort of Extremely

Preterm Infants

 

Pia Lundgren, Elisabeth Stoltz Sjöström, Magnus Domellöf, Karin Källen, Gerd Holmström, Anna-Lena Hård, Lois E. Smith, Chatarina Löfqvist, Ann Hellström

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2013 Clinical Perinatology

 

Algorithms for the Prediction of Retinopathy of Prematurity based upon Postnatal Weight Gain

 

Gil Binenbaum

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2013 Archivos Sociedad Española de Oftalmología

 

El algoritmo WINROP y otras novedades en el cribado de la retinopatía del prematuro

The WINROP algorithm and other innovations in the screening for retinopathy of prematurity

 

I. González Viejo, C. Ferrer Novella, V. Pueyo Royo

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2013 British Journal of Ophthalmology

 

Reduction in screening for retinopathy of prematurity through risk factor adjusted inclusion criteria

 

A J van Sorge, E Schalij-Delfos, F T Kerkhoff, L J van Rijn, J LA Van Hillegersberg, LA Van Liempt, O G M Peer, H J Simonz, M Termote

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2013 Lancet

 

Retinopathy of prematurity

 

Ann Hellström, Lois E H Smith, Olaf Dammann

 

2017

ACTUALIZACIÓN: ALGORITHMS TO DETECT ROP BASED IN POSTNATAL WEIGHT GAIN

2006 Archives of Ophthalmology

 

Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity

 

Chatarina Löfqvist, Eva Andersson, Jan Sigurdsson, Eva Engström, Anna-Lena Härd, Aimon Niklasson, Lois E H Smith, Ann Hesllström

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Retina

 

Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I

 

Authors: JE Moon Yoon, Dong Hoon Shin, Sang Jin Kim, Don-Il Ham, Se Woong Kang, Yun Sil Chang, Won Soon Park

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Retina

 

Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A Longitudinal Fluorescein Angiographic Study

 

Authors: Birgit Lorenz, Knut Stieger, Melanie Jager, Christine Stieger, Monika Andrassi-Darida; On behalf of the Giessen Cooperative ROP Study Group

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Ophthalmic Surgery, Lasers and Imaging Retina

 

Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity Ophthalmic Surgery, Lasers and Imaging Retina

 

Shelley Day, Annis M. Rainey, Clio A. Harper III

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Journal of Ophthalmology

 

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

 

Authors: Qinrui Hu, Yujing Bai, Xiaoli Chen, Lvzhen Huang, Yi Chen, Xiaoxin Li

 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Retina

 

Progressive retinal detachment in infants with ROP treated with IV Bevacizumab or Ranibizumab

 

Authors: YONEKAWA, WEI-CHI WU, NITULESCU, PAUL CHAN, THANOS, THOMAS, TODORICH, KIMBERLY A. DRENSER, MICHAEL T. TRESE, ANTONIO CAPONE JR

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Journal of Ophthalmology

 

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

 

Authors: Qiujing Huang, Qi Zhang, Yu Xu, Xunda Ji, Ping Fei, Jie Peng, Yi-an Li, and Peiquan Zhao

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

 

2017 Ophthalmology

 

Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors

 

Authors: Qiujing Huang, Qi Zhang, Ping Fei, Yu Xu, Jiao Lyu, Xunda Ji, Jie Peng, Yi-an Li, Peiquan Zhao

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Arquivos Brasileiros de Oftalmologia

 

The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity Processo de vascularização após injeções intravítreas de ranibizumab para retinopatia da prematuridade posterior agressiva

 

Authors: Emine Alyamaç Sukgen, Yusuf Koçluk

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 BMJ Ophthalmology

 

Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk

 

Authors: Gillian G W Adams,Catey Bunce,Wen Xing, Lucilla Butler, Vernon Long, Aravind Reddy, Annegret H Dahlmann-Noor

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 IOVS

 

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

 

Authors: Jiao Lyu, Qi Zhang, Chun-Li Chen, Yu Xu, Xun-Da Ji, Jia-Kai Li, Qiu-Jing Huang, Pei-Quan Zhao

 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 JAMA Opthalmology

 

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study

 

Authors: David K.Wallace, Raymond T. Kraker, Sharon F. Freedman, Eric R. Crouch, Amy K. Hutchinson, Amit R. Bhatt, David L. Rogers, Michael B. Yang, Kathryn M. Haider, Deborah K. VanderVeen, Michael Siatkowski, Trevanow Dean, Roy W. Beck, Michael X. Repka, Lois E. Smith, William V. Good, Mary Elizabeth Hartnett, Lingkun Kong, Jonathan M. Holmes, for the Pediatric Eye Disease Investigator Group (PEDIG)

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

 

2017 Eye and Brain

 

Review of effects of anti-VEGF treatment on refractive error

 

Helen Mintz-Hittner, Megan M Geloneck

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Ophthalmology

 

Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings

 

Domenico Lepore, Graham E. Quinn, Fernando Molle, Lorenzo Orazi, Antonio Baldascino, Marco H. Ji, Maria Sammartino, Fabio Sbaraglia, Daniela Ricci, Eugenio Mercuri

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

 

2017 British Journal of Ophthalmology

 

Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series

 

Roxane J Hillier, Alan J Connor, Ayad E Shafiq

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Case Reports in Ophthalmology

 

Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis

 

Tomoaki Higashiyama Sanae Muraki Masahito Ohji

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2017 Experimental and Therapeutic Medicine

 

Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report

 

Jianxun Wang, Daoman Xiang

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Retinal Physician

 

AntiVEGF Agents in ROP: Finding balance between efficacy and adverse events

 

Authors: Vishak J. John, Claudia G. Hooten, Nick Grisson

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of Optometry

 

Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity

 

Authors: Sengul Ozdek, Metin Unlu, Gokhan Gurelik, Berati Hasanreisoglu

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Retinal and Eye Research

 

The neural retina in retinopathy of prematurity

 

Authors: Ronald M. Hansen, Anne Moskowitz, James D. Akula, Anne B. Fulton

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of Ophthalmology

 

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior

Retinopathy of Prematurity with Vitreous Hemorrhage

 

Authors: Yu Xu, Xiaoli Kang, Qi Zhang, Qiujing Huang, Jiao Lv, and Peiquan Zhao

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Intravitreal injections of bevacizumab: timing, technique, and outcomes

 

Author: Helen A. Mintz-Hittner

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Postmortem vitreous bevacizumab levels of an infant treated for retinopathy of prematurity

 

Authors: Stephen Hypes, Orwa Nasser, Nancy Hanna, William Lawhon, Rachida Bouhenni

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of American Academy of Ophthalmology and Strabismus

 

A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity

 

Authors: Alireza Khodabande, Mohammad Reza Niyousha, Ramak Roohipoor

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 The Cochrane Library

 

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

 

Authors: Mari Jeeva Sankar, Jhuma Sankar, Manisha Mehta, Vishnu Bhat, Renuka Srinivasan

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Acta Ophthalmologica

 

Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison

 

Authors: Jinu Han, Seong Eun Kim, Sung Chul Lee, Christopher Seungkyu Lee

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of Pediatric Ophthalmology and Strabismus

 

Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity

 

Authors: Paula Larrañaga-Fragoso, Jesús Peralta, Luciano Bravo-Ljubetic, Natalia Pastora, José Abelairas-Gómez

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Ophthalmology

 

Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity

 

Brian C. Toy, Ira H. Schachar, Gavin S.W. Tan, Darius M. Moshfeghi

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Scientific Reports

 

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy

 

Authors: Joyce J.T. Chan, Carol P. S. Lam, Madeline K. M. Kwok, Raymond L. M. Wong, Gary K.Y. Lee, Winnie W.Y. Lau, Jason C. S.Yam

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Ophthalmology

 

Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy

 

Authors: Helen A. Mintz-Hittner, Megan M. Geloneck, Alice Z. Chuang

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Ophthalmology

 

Does Bevacizumab Alter Vascularization Potential in Retinopathy of Prematurity?

 

Authors: Maram Isaac, Kamiar Mirskandari, Nasrin Tehrani

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Ophthalmology

 

Bevacizumab for Retinopathy of Prematurity: Treatment When Pathology Is Embedded in a Normally Developing Vascular System

 

Author: William V. Good

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Medical Sciences Monitor

 

Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis

 

Authors: Simona D. Nicoar?, Anne C. ?tef?nu?, Constanta Nascutzy, Gabriela C. Zaharie, Laura E. Toader, Tudor C. Drugan

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Acta Ophthalmologica

 

Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity

 

Authors: Reza Karkhaneh, Alireza Khodabande, Mohammad Riazi-Eafahani, Ramak Roohipoor, Fariba Ghassemi, Marjan Imani, Afsar Dastjani Farahani, Nazanin Ebrahimi Adib, Hamidreza Torabi

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Ophthalmic Surgery, Lasers and Imaging Retina

 

Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab

 

Authors: Laura L. Snyder, Jose Maria Garcia-Gonzalez, Michael J. Shapiro, Michael P. Blair

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 PLOS ONE

 

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

 

Authors: Reyin Lien, Mu-Hsien Yu, Kuang-Hung Hsu, Pei-Ju Liao, Yen-Po Chen, ChiChun Lai, Wei-Chi Wu

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Anti-VEGF treatment for ROP: which drug and what dose?

 

David K. Wallace

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: A literature review

 

Authors: Kaveh Abri Aghdam, Joobin Khadamy, Khalil Ghasemi Falavarjani, Irena Tsui 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Clinical Ophthalmology

 

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

 

Authors: Chun-Ju Lin, Yi-Yu Tsai

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Current Opinion in Ophthalmology

 

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

 

Authors: Jinali R. Patel, Sinthu S. Ranjan, Barry N. Wasserman

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Pediatrics

 

Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity

 

Authors: Lu-Hsuan Wu, Yea-Huei Kao Yang, Chyi-Her Lin, Yuh-Jyh Lin, Ching-Lan Cheng

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2016 Eye and Brain

 

Review of effects of anti-VEGF treatment on refractive error

 

Helen Mintz-Hittner, Geloneck MM

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Arquivos Brasileiros de Oftalmologia

 

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

 

Authors: Muhammet Kazim Erol, Deniz Turgut Coban, Esin Sogutlu Sari, Ahmet Burak Bilgin, Berna Dogan, Ozdemir Ozdemir, Zuhal Ozen Tunay

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Arquivos Brasileiros de Oftalmologia

 

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.

 

Authors: Murat Gunay, Gokan Celik, Betul Onal Gunay, Alev Aktas

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Journal Of Pediatric Ophthalmology and Strabismus

 

Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prematurity: What We Know After 7 Years

 

Authors: Michael A. Klufas, Paul Chan

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Ophthalmology

 

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis

 

Christopher K. Hwang, G. Baker Hubbard, Amy K. Hutchinson, Scott R. Lambert

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Graefes Archive for Clinical and Experimental Ophthalmology

 

Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity: 27 month follow-up results from Turkey

 

Authors: Huseyin Yetik, Murat Gunay, Sarkis Sirop, Ziya Salihoglu

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Archivos de la Sociedad Española de Oftalmología

 

Uso off-label de bevacizumab intravítreo en retinopatía del prematuro severa

 

L.E. Alba, R.A. Zaldua, R.A. Masini

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

 

2015 Journal of Ophthalmology

 

Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

 

Authors: Simona Delia Nicoara, Constanta Nascutzy, Criustina Cristian, Iulian Irimescu, Anne Claudia Stefanut, Gabriela Zaharie, Tudor Drugan 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Canadian Journal of ophthalmology

 

Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent

 

Authors: Kamiar Mireskandari, Megan E. Collins, Nasrin Tehrani

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Ophthalmologica

 

Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy

 

Authors: Hsi-Kung Kuo, Ting Sun, Mei-Yung Chung, Yi-Hao Chen 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 International Ophthalmology Clinics

 

Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity

 

Authors: Ilya Leskov, Shizuo Mukai

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Japanese Journal of Ophthalmology

 

Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes

 

Authors: Yukiko Futamura, Tetsu Asami, Norie Nonobe, Shu Kachi, Yasuki Ito, Yoshiaki Sato, Masahiro Hayakawa, Hiroko Terasaki

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Journal of Pediatric Ophthalmology and Strabismus

 

Ultra-Low Dose of Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity

 

Authors: Alan J. Connor, Vasileios T. Papastavrou, Roxane J. Hillier, Ayad Shafiq

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser

 

Authors: Maram Isaac, Kamiar Mireskandari, Nasrin Tehrani

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 BMC Ophthalmology

 

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

 

Authors: Marcel N Menke, Carten Framme, Mathias Nelle, Markus R Berger, Veit Sturm, Sebastian Wolf

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Retina

 

Plasma concentrations of vascular endothelial growth factor (VEGFafter bevacizumab intravitreal injection in infants with retinopathy of prematurity

 

Authors: Yoo Rha Hong, Young Ho Kim, Soo Young Kim, Gi Yup Nam, Hee Jong Cheon, San Joon Lee

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Journal of Pediatrics and Child Health

 

Retinopathy of prematurity: New developments bring concern and hope

 

Author: Brian A Darlow

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 IOVS

 

Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity

 

Authors: Lingkun Kong,Amit R. Bhatt, Ann B. Demny, David K. Coats, Alexa Li, Effie Z. Rahman, O’Brian E. Smith, Paul G. Steinkuller

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 JAMA Ophthalmology

 

Serum Levels of Vascular Endothelial Growth Factor and Related Factors After Intravitreous Bevacizumab Injection for Retinopathy of Prematurity

 

Authors: Wei-Chi Wu, Reyin Lien, Pei-Ju Liao, Nan-Kai Wang, Yen-Po Chen, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang, Chi-Chun Lai

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Retina

 

Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity: Comparison Between Ranibizumab and Bevacizumab

 

Authors: San-Ni Chen, Iebin Lian, Ya-Chi Hwang, Yi-Hsing Chen, Yao-Chung Chang, Kun-Hsien Lee, Chih-chun Chuang, Wei-Chi Wu

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2015 Retina

 

Efficacy of Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents for Stage 4 Retinopathy of Prematurity

 

Authors: Hui-Chen Cheng, Shui-Mei Lee, Yi-Ting Hsieh, Po-Kang Lin

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Journal of Ophthalmology

 

Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity

 

Authors: Rebecca Kim, Yu Cheol Kim

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Clinical Perinatology

 

Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity

 

Author: M. Elizabeth Hartnett

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser

 

Authors: Wendy Chen, Gil Binenbaum, Karen Karp,Agnieshka Baumritter, Denise J. Pearson, Albert M. Maguire, Graham E. Quinn

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Ophthalmology

 

Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity: Report on Fluorescein Angiographic Findings

 

Authors: Domenico Lepore, Graham E. Quinn, Fernando Molle, Antonio Baldascino, Lorenzo Orazi, Maria Sammartino, Velia Purcaro, Carmen Giannantonio, Patrizia Papacci, Costantino Romagnoli

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Acta Ophthalmologica

 

Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies

 

Authors: Sang Woo Park, Hyun Ho Jung, Hwan Heo

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Canadian Journal of Ophthalmology

 

Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity

 

Authors: David Ehmann, Mark Greve

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Acta Ophthalmologica

 

Intravitreal low-dosage bevacizumab for retinopathy of prematurity

 

Authors: Bjorn C. Harder, Stefan von Baltz, Jost B. Jonas, Frank C. Schlichtenbrede

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Journal of Pediatric Ophthalmology and Strabismus

 

A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.

 

Authors: Yaz Y, Erol N, Gursoy H, Basmak H, Bilgec MD

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Eye

 

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

 

Authors: Y-H Chen, S-N- Chen, R-I Lien, C-P Shih

 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 JAMA Ophthalmology

 

Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial

 

Authors: Megan M. Geloneck, Alice Z. Chuang, W. Lloyd Clark, Michael G. Hunt, Alan A. Norman, Eric A. Packwood, Khaled A. Tawansy, Helen A. Mintz-Hittner, for the BEAT-ROP Cooperative Group

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Japanese Journal of Ophthalmology

 

Intravitreal injection of bevacizumab for retinopathy of prematurity

 

Authors: Kazuki Kuniyoshi, Koji Sugioka, Hiroyuki Sakuramoto, Shunji Kusaka, Norihisa Wada, Yoshikazu Shimomura

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Acta Ophthalmologica

 

Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity

 

Authors: Sarah Moran, Michael O’Keefe, Claire Hartnett, Bernadette Lanigan, John Murphy, Veronica Donoghue

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2014 Retina

 

Combined Intravitreal Bevacizumab Injection and Zone I Sparing Laser Photocoagulation in Patients with Zone I Retinopathy of Prematurity

 

Authors: Jaeryung Kim, Sang Jin Kim, Yun Sil Chang, Won Soon Park

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Clinical Perinatology

 

Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

 

Authors: David K. Wallace, Katherine Y. Wu

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab

 

Authors: Shaun Ittiara, Michael P. Blair, Michael J. Shapiro, Steven J. Lichtenstein

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Journal of Optometry

 

Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity

 

Authors: Sengul Ozdek, Metin Unlu, Gokhan Gurelik, Berati Hasanreisoglu

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 American Journal of Ophthalmology

 

An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan

 

Authors: Wei-Chi Wu, Hsi-Kung Kuo, Po-Ting Yeh, Chung-May Yang, Chi-Chun Lai, San-Ni Chen

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Eye

 

Prolonged follow-up period following intravitreal bevacizumab injection for stage 3 þ retinopathy of prematurity

 

Authors: TA de Klerk, DY Park, S Biswas 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Journal of Pediatric Ophthalmology and Strabismus

 

Dramatic Regression of Persistent Tunica Vasculosa Lentis Associated With Retinopathy of Prematurity Following Treatment With Intravitreal Bevacizumab

 

Authors: Darin R. Goldman, Caroline R. Baumal

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Pediatrics International

 

Intravitreal bevacizumab monotherapy for retinopathy of prematurity

 

Alparslan S¸ahin,1 Muhammed Sahin, Abdullah Kürsat Cingü, Yasin Ç?nar, Fatih Mehmet Türkcü, Harun Yüksel, Savas¸ Kaya, Seyhmus Ar?, I?hsan Çaça

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 JAMA Ophthalmology

 

Recurrence of Retinopathy of Prematurity Following Bevacizumab Monotherapy: Is It Only the Tip of the Iceberg?

 

Authors: Kamiar Mireskandari, Gillian G. W. Adams, Nasrin N. Tehrani

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Acta Ophthalmologica

 

Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

 

Authors: Yu Xu, Qi Zhang, Xiaoli Kang, Ying Zhu, Jiakai Li, Yiye Chen, Peiquan Zhao

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 American Journal of Ophthalmology

 

Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

 

Authors: Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jonas JB

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Acta Ophthalmologica

 

What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

 

Author: Ulrich Spandau

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2013 Acta Ophthalmologica

 

Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?

 

Authors: Ulrich Spandau, Zoran Tomic, Uwe Ewald, Eva Larsson, Hanna Åkerblom, Gerd Holmström

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Taiwan Journal of Ophthalmology

 

Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: A preliminary report

 

Authors: Chun-Ju Lin, San-Ni Chen, Chien-Chi Tseng, Yao-Chung Chang, Jiunn-Feng Hwang

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Early Human Development

 

Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors

 

Author: Helen A. Mintz-Hittner

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 American Journal of Ophthalmology

 

Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

 

Authors: Tatsuhiko Sato, Kazuko Wada, Hitomi Arahori, Noriyuki Kuno, Kenji Imoto, Chiharu Iwahashi-Shima, Shunji Kusaka

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Journal of Pediatric Ophthalmology and Strabismus

 

An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity

 

Authors: Mihai Mititelu, Khurram M. Chaudhary, Ronni M. Lieberman

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Journal of Pediatric Ophthalmology and Strabismus

 

Different Refractive Errors in Triplets With Retinopathy of Prematurity Treated With Bevacizumab

 

Authors: Chien-Chi Tseng, San-Ni Chen, Jiunn-Feng Hwang, Chun-Ju Lin

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 JAMA Ophthalmology

 

Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of Prematurity

 

Authors: Ravi Patel, Michael Blair, Michael Shapiro

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 JAMA Ophthalmology

 

Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.

 

Authors: Harder BC, von Baltz S, Schlichtenbrede FC, Jonas JB

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Acta Paediatrica

 

Is Avastin the right choice of treatment for retinopathy of prematurity?

 

Author: Anna Käll

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Eye

 

Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity

 

Authors: BJ Lee, JH Kim, H Heo, YS Yu

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Journal of Maternal, Fetal & Neonatal Medicine

 

Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment: A case series

 

Authors: Carlo Dani, Saverio Frosini, Pina Fortunato, Giovanna Bertini, Simone Prates4, Liliana Pollazz, Roberto Caputo, Agostino La Torre

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 JAMA Ophthalmology

 

Reactivation of Retinopathy of Prematurity After Bevacizumab Injection

 

Authors: Jennifer Hu, Michael P. Blair, Michael J. Shapiro, Steven J. Lichtenstein, John M. Galasso, Rashmi Kapur

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2012 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?

 

Author: Robert Avery

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2011 Ophthalmology

 

Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan

 

Authors: Wei-Chi Wu, Po-Ting Yeh, San-Ni Chen, Chung-May Yang, Chi-Chun Lai, Hsi-Kung Kuo

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2011 Middle East African Journal of Ophthalmology

 

Early Experience with Intravitreal Bevacizumab Combined with Laser Treatment for Retinopathy of Prematurity

 

Authors: Seemant Raizada, Jamal Al Kandari, Ahmad Al Foudari

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2011 Ophthalmology

 

Retinopathy of Prematurity in the Time of Bevacizumab: Incorporating the BEAT-ROP Results into Clinical Practice

 

Authors: Darius M. Moshfeghi, California Audina M. Berrocal

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2011 Acta Paediatrica

 

On the use of antiangiogenetic medications for retinopathy of prematurity.

 

Hard AL, Hellstrom A

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2011 New England Medical Journal

 

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

 

Authors: Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang, for the BEAT-ROP Cooperative Group

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2010 Graefes Archives for Clinical and Experimental Ophthalmology

 

Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels

 

Authors: Joo Yong Lee, Ju Byung Chae, Sung Jae Yang, Young Hee Yoon, June-Gone Kim

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2010 Clinical Ophthalmology

 

Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity

 

Authors: Raul Velez-Montoya, Carmen Clapp, Jose Carlos Rivera, Gerardo Garcia-Aguirre, Virgilio Morales-Cantón, Jans Fromow-Guerra, Jose Luis Guerrero-Naranjo, Hugo Quiroz-Mercado

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2010 Journal of American Academy of Pediatric Ophthalmology and Strabismus

 

Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity

 

Authors: Janice C. Law, Franco M. Recchia, David G. Morrison, Sean P. Donahue, Robert L. Estes

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2010 JAAPOS

 

Avastin as monotherapy for retinopathy of prematurity

 

Author: Helen A. Mintz-Hittner

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2009  Current Opinion in Pediatrics

 

Antivascular endothelial growth factor for retinopathy of prematurity

 

Authors: Helen A. Mintz-Hittner, Leah M. Best

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2009 Developmental Ophthalmology

 

Anti-Angiogenic Therapy in the Management of Retinopathy of Prematurity

 

Author: Kimberly A. Drenser

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2009 American Journal of Ophthalmology

 

A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity

 

Authors: Jonathan A. Micieli, Michael Surkont, Andrew F. Smith

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2009 Eye (London)

 

Paradoxical vascular–fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity

 

Authors: Luz Consuelo Zepeda-Romero, JA Liera-Garcia, JA Gutiérrez-Padilla, CI Valtierra-Santiago, LJ Cardenas-Lamas

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2009 Retina

 

Concentration of VEGF in aqueous humor of eyes with advanced ROP before and after intravitreal injection of bevacizumab

 

Authors: N Nonobe, S Kachi, M Kondo, Y Takai, K Takemoto, A Nakayama, M Hayakawa, H Terasaki

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Retina

 

Antiangiogenic Therapy with Intravitreal Bevacizumab for Retinopathy of Prematurity

 

Authors: Hugo Quiroz-Mercado, Maria Ana Martinez-Castellanos, Myriam L Hernandez-Rojas, Nelida Salazar-Teran, Robinson Vernon Paul Chan

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Retina

 

Intravitreal Injection of Bevacizumab (Avastin) for Treatment of Stage 3 Retinopathy of Prematurity in Zone I or Posterior Zone II

 

Authors: Helen A. Mintz-Hittner, Ronald Kuffel Jr.

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Retina

 

Off-label use of Intravitreal Bevacizumab (Avastin) for Salvage Treatment in Progressive Threshold Retinopathy of Prematurity

 

Authors: Geeta A. Lalwani, Audina M. Berrocal, Timothy G. Murray, Maria Buch, Scott Cardone, Ditte Hess, Rose A. Johnson, Carmen A. Puliafito

 

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Graefes Archives of Clinical and Experimental Ophthalmology

 

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity

 

Authors: Shigeru Honda, Hiroaki Hirabayashi, Yasutomo Tsukahara, Akira Negi

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Acta Ophthalmologica

 

Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity

 

Authors: Roberto dell’Omo, Avinash Kulkarni, Wendy A. Franks

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2008 Archives of Ophthalmology

 

Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study

 

Authors: Lingkun Kong, Helen A. Mintz-Hittner, Rebecca L. Penland, Francis L. Kretzer, Patricia Chévez-Barrios

 

 

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2007 Indian Journal of Ophthalmology

 

Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

 

Parag K Shah, V Narendran, Khaled A Tawansy,  A Raghuram, Kalpana Narendran

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2007 Ophthalmic Surgery Lasers Imaging

 

Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity

 

António Travassos, Susana Teixeira, Pinto Ferreira, Isaura Regadas, Ana Sofia Travassos, Florindo Esteves Esperancinha, Isabel Prieto, Graça Pires, Robert van Velze, A. Valido, Maria do Céu Machado

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2007 Graefes Archives for Clinical and Experimental Ophthalmology

 

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

 

Eun Jee Chung, Ji Hyun Kim, Hyun Seok Ahn, Hyoung Jun Koh

2017

ACTUALIZACIÓN: ANTIVEGF EN ROP

2006 Retina

 

Testing Intravitreal Toxicity of Bevacizumab (Avastin) 

 

Roberta P. A. Manzano, Gholan A. Peyman, Palwasha Khan, Muhamet Kivilcim

2017

The Cutting Edge in ROP care

 

THE CUTTING EDGE OF RETINOPATHY OF PREMATURITY CARE:

Expanding the Boundaries of Diagnosis and Treatment.

 

Authors: Yonekawa YThomas BJThanos ATodorich BDrenser KATrese MTCapone A Jr.

 

PURPOSE: To discuss the latest advances and controversies in the diagnosis and care of infants with ROP.

 

METHODS: Literature review.

 

RESULTS: ROP remains a major global issue. Industrialized nations now treat profoundly premature infants with posterior and aggressive disease, and middle-income nations are experiencing ROP epidemics. Remote digital imaging may address the decreasing ratio of ROP providers to premature infants, in addition to improving patient care. Widefield angiography, optical coherence tomography, and the Wnt signaling pathway have provided new insights into ROP pathogenesis. Anti-vascular endothelial growth factor treatment is increasing in popularity, but the dearth of information to guide dosing, unpredictable reactivation, persistent vascular abnormalities, the "crunch" phenomenon, and the presently unknown effects of systemic vascular endothelial growth factor suppression remain issues to continue investigating. Neurodevelopmental delay has been raised as a potential consequence, but the evidence currently is weak. Vitrectomy is the treatment of choice for Stages 4 and 5. Illumination techniques, ab interno incisions, plasmin-assisted vitrectomy, staged surgery in the interest of corneal clearing for advanced Stage 5, and immediate sequential bilateral vitreoretinal surgery, are useful techniques.

 

CONCLUSION: We are making progress in ROP management. Our goal as clinicians is to continue expanding the boundaries of our abilities to keep this blinding disease in check globally.

 

 

 

2015

Case Report Bilateral Coats’ Disease Combined with Retinopathy of Prematurity

 

Publicado en el Case Reports in Ophthalmological Medicine Volume 2015,

 

Huseyin Gursoy,1 Nazmiye Erol,1 Mustafa Deger Bilgec,1 Hikmet Basmak,1Ozden Kutlay,2 and Huseyin Aslan2

 

1Department of Ophthalmology, Eskis¸ehir Osmangazi University Medical Faculty, 26180 Eskis¸ehir, Turkey
2Department of Medical Genetics, Eskis¸ehir Osmangazi University Medical Faculty, 26180 Eskis¸ehir, Turkey

 

 

ABSTRACT

 

To report a case of bilateral Coats’ disease combinedwith retinopathy of prematurity (ROP). Case. Retinal vascularization was complete in the right eye, whereas zone III, stage 3 ROP and preplus disease were observed in the left eye at 43 weeks of postmenstrual age (PMA) in a 31-week premature, 1200-g neonate. Intraretinal exudates developed and retinal hemorrhages increased in the left eye at 51 weeks of PMA. Diode laser photocoagulation (LP) was applied to the left eye. Exudates involved the macula, and telangiectatic changes developed one month following LP. Additional LP was applied to the left eye combined with intravitreal bevacizumab (IVB) injection at 55 weeks of PMA. Disease regressed onemonth after the additional therapy. At the 14-month examination of the baby, telangiectatic changes and intraretinal exudates were observed in the right eye.Diode LP was applied to the right eye combinedwith IVBinjection. Exudates did not resolve completely, and cryotherapy was applied onemonth following LP. Retinal findings regressed three months following the cryotherapy. Conclusion. This is the first report of presumed bilateral Coats’ disease combined with ROP. If Coats’ disease could be diagnosed at early stages, it would be a disease associated with better prognosis.

 

 

2013

Retinopatía del prematuro

 

Grupo ROP México

 

2010

Guidelines for ROP screening and treatment in Latin American Countries

CBM, Vision 2020 Americas, IAPB

 

Andrea Zin

Marco A. de la Fuente Torres

Clare Gilbert

Graham E. Quinn

2008

Prevención de la ceguera en la infancia por retinopatía del prematuro

Grupo de Trabajo Colaborativo Multicéntrico: "Prevención de la ceguera en la infancia por Retinopatía del Prematuro

 

Ministerio de Salud

Presidencia de la Nación

Republica Argentina

 

 

2008

Retinopatía del Prematuro

Alejandro Vázquez De Kartzow

 

Guía Clínica Diagnóstica

Viña del Mar

Chile

 

 

 

2007

Guidelines for ROP screening and treatment in Latin American Countries

Vision 2020 IAPB

 

Christoffel Blindenmission

International Centre for Eye Health

London School Hygiene and Tropical Medicine

 

Archivos para Download:

1) English version

2) Spanish Version

 

 

 

2007

Manejo de la Retinopatía del Recién Nacido Prematuro

Lineamento Técnico

 

Secretaria de Salud

Centro Nacional de Equidad de Género y Salud Reproductiva

Ciudad de México DF

México

2001

Childhood blindness in the context of VISION 2020 —The Right to Sight

Bulletin of the World Health Organization

 

Clare Gilbert & Allen Foster

 

The major causes of blindness in children vary widely from region to region, being largely determined by socioeconomic development, and the availability of primary health care and eye care services. In high-income countries, lesions of the optic nerve and higher visual pathways predominate as the cause of blindness, while corneal scarring from measles, vitamin A deficiency, the use of harmful traditional eye remedies, and ophthalmia neonatorum are the major causes in low-income countries.

 

Retinopathy of prematurity is an important cause in middle-income countries. Other significant causes in all countries are cataract, congenital abnormalities, and hereditary retinal dystrophies. It is estimated that, in almost half of the children who are blind today, the underlying cause could have been prevented, or the eye condition treated to preserve vision or restore sight.

 

The control of blindness in children is a priority within the World Health Organization’s VISION 2020 programme. Strategies need to be region specific, based on activities to prevent blindness in the community - through measles immunization, health education, and control of vitamin A deficiency and the provision of tertiary-level eye care facilities for conditions that require specialist management.